Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 2:17 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 4,802 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Allergy Clear all
Completed Phase 1Phase 2 Interventional Results available

Carboplatin/Pralatrexate in Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer

NCT01188876
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer
Interventions
carboplatin, pralatrexate, Folic Acid, Vitamin B12 Injection
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 19, 2018 · Synced Oct 22, 2026, 2:17 AM EDT
Recruiting Phase 2 Interventional

Effect of Tirzepatide and Bimagrumab on Body Composition, Insulin Sensitivity, and Bone in Adults With Obesity

NCT05933499
View directory record Official record
Conditions
Obesity
Interventions
Bimagrumab, Tirzepatide, Calcium/Vitamin D, Lifestyle and nutrition counseling
Drug · Dietary Supplement · Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 22, 2026, 2:17 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Benralizumab to Reduce OCS Use in Patients With Uncontrolled Asthma on High Dose Inhaled Corticosteroid Plus LABA and Chronic OCS Therapy

NCT02075255
View directory record Official record
Conditions
Asthma
Interventions
Benralizumab, Placebo
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
20
States / cities
Los Angeles, California • Centennial, Colorado • Denver, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2018 · Synced Oct 22, 2026, 2:17 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety, Tolerability and Pharmacokinetics Study of Topical Ointment YR001 in Adult Healthy Volunteers

NCT05718921
View directory record Official record
Conditions
Atopic Dermatitis, Psoriasis
Interventions
YR001 Dose A on low body surface area, YR001 Dose A on middle body surface area, YR001 Dose A on high body surface area, YR001 Dose B on low body surface area, YR001 Dose B on middle body surface area, YR001 Dose B on high body surface area, Placebo on low body surface area, Placebo on middle body surface area, Placebo on high body surface area, YR001 Dose A on high body surface area twice daily, YR001 Dose B on high body surface area twice daily, Placebo on high body surface area twice daily
Drug
Lead sponsor
Hangzhou Yirui Pharmaceutical Technology Co., Ltd
Industry
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Encinitas, California
Source: ClinicalTrials.gov public record
Updated Jan 24, 2024 · Synced Oct 22, 2026, 2:17 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Subjects With Severe Uncontrolled Refractory Asthma

NCT01691521
View directory record Official record
Conditions
Asthma
Interventions
Mepolizumab IV, Mepolizumab SC, IV Placebo, SC Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
580 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
21
States / cities
Birmingham, Alabama • Newport Beach, California • Riverside, California + 17 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2018 · Synced Oct 22, 2026, 2:17 AM EDT
Completed No phase listed Observational

Screening Protocol for Genetic Diseases of Allergic Inflammation

NCT00852943
View directory record Official record
Conditions
Eosinophilic Disease, Immune Deficiency, HaTS, Urticaria Anaphylaxis, Elevated IgE Level
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Day to 99 Years
Enrollment
834 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 22, 2026, 2:17 AM EDT
Completed Phase 2 Interventional Results available

Safety and Pharmacokinetics of Patanase in Pediatric Patients 2 to < 6 Years of Age

NCT00794144
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
Olopatadine Hydrochloride Nasal Spray 0.6%, Olopatadine Hydrochloride Nasal Spray Vehicle
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
2 Years to 5 Years
Enrollment
132 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Waco, Texas
Source: ClinicalTrials.gov public record
Updated Mar 4, 2010 · Synced Oct 22, 2026, 2:17 AM EDT
Terminated Phase 2 Interventional

A Safety and Efficacy Study of Xolair in Peanut Allergy

NCT00086606
View directory record Official record
Conditions
Allergy
Interventions
Xolair (omalizumab)
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
6 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 21, 2013 · Synced Oct 22, 2026, 2:17 AM EDT
Recruiting Phase 4 Interventional

Ventilation and Perfusion in Asthmatics

NCT07426458
View directory record Official record
Conditions
Asthma
Interventions
Albuterol Sulfate, Albuterol-Budesonide
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 22, 2026, 2:17 AM EDT
Terminated Phase 2 Interventional

Gemzar (Gemcitabine) and Alimta (Pemetrexed) in the Treatment of Patients With Recurrent Platinum-Sensitive and Platinum-Resistant Ovarian or Peritoneal Cancer

NCT00055432
View directory record Official record
Conditions
Ovarian Cancer, Peritoneal Cancer
Interventions
Gemzar and Alimta
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 15, 2006 · Synced Oct 22, 2026, 2:17 AM EDT
Completed Phase 3 Interventional Results available

New Breath Actuated MDI Symbicort Compared to Symbicort pMDI and Budesonide pMDI for 12 Weeks Twice a Day

NCT01360021
View directory record Official record
Conditions
Asthma
Interventions
Symbicort, Budesonide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years and older
Enrollment
214 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
31
States / cities
Huntington Beach, California • Long Beach, California • Los Angeles, California + 28 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2014 · Synced Oct 22, 2026, 2:17 AM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Safety, Tolerability, Pharmacokinetics, and Preliminary Pharmacodynamics of QBW251 in Healthy Subjects and Cystic Fibrosis Patients

NCT02190604
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Placebo, QBW251
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
153 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
9
States / cities
Birmingham, Alabama • Denver, Colorado • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2020 · Synced Oct 22, 2026, 2:17 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Reducing Asthma Disparities Through School-Based Telemedicine for Rural Children

NCT01167855
View directory record Official record
Conditions
Asthma, Quality of Life, Children
Interventions
Asthma Education Sessions, Asthma Health Assessment via Telemonitoring, Provider Treatment Prompt, School Absenteeism, Prescription Filling Profile
Other
Lead sponsor
Arkansas Children's Hospital Research Institute
Other
Eligibility
7 Years to 14 Years
Enrollment
823 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2017
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated May 16, 2017 · Synced Oct 22, 2026, 2:17 AM EDT
Terminated Phase 4 Interventional Results available

Study Of RV-39 In Patients Who Also Have Asthma

NCT00503009
View directory record Official record
Conditions
Asthma
Interventions
fluticasone propionate/salmeterol, fluticasone propionate, placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 40 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 28, 2016 · Synced Oct 22, 2026, 2:17 AM EDT
Completed Phase 2 Interventional Results available

Dose Ranging Efficacy And Safety With Mepolizumab in Severe Asthma

NCT01000506
View directory record Official record
Conditions
Asthma
Interventions
Mepolizumab 750, Mepolizumab 250, Mepolizumab 75, Placebo saline
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years to 65 Years
Enrollment
621 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
21
States / cities
Long Beach, California • Los Angeles, California • Riverside, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2018 · Synced Oct 22, 2026, 2:17 AM EDT
Terminated Phase 3 Interventional Results available

Study of Efficacy and Safety of Ligelizumab in Chronic Spontaneous Urticaria Patients Who Completed a Previous Study With Ligelizumab

NCT04210843
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
Ligelizumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
1,033 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
39
States / cities
Birmingham, Alabama • Gilbert, Arizona • Litchfield Park, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2024 · Synced Oct 22, 2026, 2:17 AM EDT
Terminated Phase 2 Interventional Results available

An Efficacy and Safety Study of JNJ-26113100 in the Treatment of Adult Atopic Dermatitis

NCT00455429
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Placebo, JNJ-26113100 (50 mg) once daily, JNJ-26113100 (100 mg) once daily, JNJ-26113100 (100 mg) twice daily, JNJ-26113100 (250 mg) twice daily
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years to 65 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
19
States / cities
Huntsville, Alabama • Los Angeles, California • Sacramento, California + 16 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2014 · Synced Oct 22, 2026, 2:17 AM EDT
Completed No phase listed Observational

6 Minute Propulsion Test Sensitivity to Increased Aerobic Capacity

NCT01184729
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
Not listed
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 65 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 22, 2014 · Synced Oct 22, 2026, 2:17 AM EDT
Completed Phase 4 Interventional

Pimecrolimus Cream 1% Plus Topical Corticosteroid in Patients (2-17 Years of Age) With Severe Atopic Dermatitis

NCT00121381
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Pimecrolimus plus topical corticosteroid (TCS), Pimecrolimus vehicle (Placebo) plus topical corticosteroid (TCS)
Drug
Lead sponsor
Novartis
Industry
Eligibility
2 Years to 17 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
13
States / cities
Huntington Beach, California • San Diego, California • Denver, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 15, 2008 · Synced Oct 22, 2026, 2:17 AM EDT
Enrolling by invitation Phase 3 Interventional

Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria

NCT07256392
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
barzolvolimab, Standard of Care
Biological · Other
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
1,370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
43
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Bakersfield, California + 35 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 22, 2026, 2:17 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy and Safety of IDP-124 Lotion for the Treatment of Moderate to Severe Atopic Dermatitis in Pediatric and Adult Subjects (301)

NCT03002571
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
IDP-124 Lotion, IDP-124 Vehicle Lotion
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
2 Years and older
Enrollment
338 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Fort Lauderdale, Florida
Source: ClinicalTrials.gov public record
Updated May 8, 2023 · Synced Oct 22, 2026, 2:17 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Assess the Safety and Efficacy of ZPL389 With TCS/TCI in Atopic Dermatitis Patients

NCT03948334
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
ZPL389 30mg, ZPL389 50mg, TCS and/or TCI
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
2
States / cities
Litchfield Park, Arizona • Fairborn, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 8, 2021 · Synced Oct 22, 2026, 2:17 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations

NCT06052267
View directory record Official record
Conditions
Asthma
Interventions
TEV-56248, Albuterol sulfate
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D LLC
Industry
Eligibility
4 Years and older
Enrollment
2,772 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
157
States / cities
Birmingham, Alabama • Dothan, Alabama • Paradise Valley, Arizona + 113 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 22, 2026, 2:17 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

The Severe Asthma Research Program III-Boston Clinical Site

NCT01761630
View directory record Official record
Conditions
Asthma
Interventions
Not listed
Lead sponsor
Elliot Israel, MD
Other
Eligibility
6 Years to 60 Years
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2021
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 12, 2021 · Synced Oct 22, 2026, 2:17 AM EDT